Welcome to our dedicated page for PAVmed Series Z Warrant SEC filings (Ticker: PAVMZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on PAVmed Series Z Warrant's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into PAVmed Series Z Warrant's regulatory disclosures and financial reporting.
PAVmed Inc. disclosed that its subsidiary, Lucid Diagnostics, completed an underwritten public offering of 28,750,000 shares of Lucid Diagnostics common stock at $1.00 per share, including full exercise of a 3,750,000-share underwriter option. After underwriting discounts and estimated offering expenses, the transaction is expected to generate approximately $26.9 million in net proceeds. Lucid Diagnostics intends to use the proceeds for working capital and general corporate purposes.
The filing is a straightforward capital raise by a subsidiary rather than PAVmed directly and provides a liquidity infusion for Lucid Diagnostics to support operations or near-term needs. No additional financial results, changes in ownership percentages, or specific allocations of the proceeds were disclosed in the text provided.
PAVmed Inc.'s Schedule 13G shows that Sargent Investment Group, LLC reports beneficial ownership of 1,006,300 common shares, representing 5.79% of the class. The filing identifies Sargent as an investment adviser organized in Maryland and indicates the position is held in the ordinary course of business as a passive holding under the Schedule 13G rules.
The filing discloses that Sargent does not hold sole voting power over the shares while it does report power to dispose of or direct disposition for the full amount. The statement also notes that other persons may have rights to dividends or sale proceeds, implying the economic interests are held on behalf of others rather than reflecting a controlling stake.
PAVmed Inc. furnished a Form 8-K dated August 14, 2025 reporting that it issued a press release announcing its financial results for the fiscal quarter ended June 30, 2025 and providing a business update. The press release is attached as Exhibit 99.1 and an Inline XBRL cover page is included as Exhibit 104. The company states the furnished information shall not be deemed "filed" under the Exchange Act nor incorporated by reference except as expressly stated. The report is signed by Dennis McGrath, President and Chief Financial Officer.